- Home
- RIGL vs TCMD Comparison
RIGL vs TCMD Comparison
Compare RIGL & TCMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- TCMD
- Stock Information
- Founded
- RIGL 1996
- TCMD 1995
- Country
- RIGL United States
- TCMD United States
- Employees
- RIGL N/A
- TCMD N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- TCMD Medical/Dental Instruments
- Sector
- RIGL Health Care
- TCMD Health Care
- Exchange
- RIGL Nasdaq
- TCMD Nasdaq
- Market Cap
- RIGL 486.4M
- TCMD 427.6M
- IPO Year
- RIGL 2000
- TCMD 2016
- Fundamental
- Price
- RIGL $20.99
- TCMD $17.54
- Analyst Decision
- RIGL Buy
- TCMD Hold
- Analyst Count
- RIGL 5
- TCMD 1
- Target Price
- RIGL $34.80
- TCMD N/A
- AVG Volume (30 Days)
- RIGL 216.6K
- TCMD 199.9K
- Earning Date
- RIGL 03-04-2025
- TCMD 02-18-2025
- Dividend Yield
- RIGL N/A
- TCMD N/A
- EPS Growth
- RIGL N/A
- TCMD N/A
- EPS
- RIGL 0.22
- TCMD 0.65
- Revenue
- RIGL $157,374,000.00
- TCMD $285,051,000.00
- Revenue This Year
- RIGL $51.34
- TCMD $8.83
- Revenue Next Year
- RIGL $15.75
- TCMD $9.86
- P/E Ratio
- RIGL $94.25
- TCMD $27.15
- Revenue Growth
- RIGL 21.65
- TCMD 5.31
- 52 Week Low
- RIGL $7.48
- TCMD $11.12
- 52 Week High
- RIGL $29.82
- TCMD $21.10
- Technical
- Relative Strength Index (RSI)
- RIGL 55.77
- TCMD 50.42
- Support Level
- RIGL $20.98
- TCMD $17.09
- Resistance Level
- RIGL $23.01
- TCMD $18.51
- Average True Range (ATR)
- RIGL 1.40
- TCMD 0.53
- MACD
- RIGL 0.31
- TCMD -0.01
- Stochastic Oscillator
- RIGL 70.13
- TCMD 31.88
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About TCMD Tactile Systems Technology Inc.
Tactile Systems Technology Inc is a medical technology company. The company is engaged in developing and providing medical devices for the treatment of chronic diseases. The firm's proprietary platform flexitouch system provides a home-based solution for lymphedema patients. The entire system is another home solution for patients with chronic swelling and actitouch system for chronic venous insufficiency patients that may be worn throughout the day.